PROSTATE CANCER

This study tests whether giving an extra-high radiation dose directly to the main tumor, while treating the rest of the prostate with standard doses, can cure intermediate-risk prostate cancer or keep it from coming back longer. About 91 men will receive this MR-guided, ultra-sho…

This early-stage study tests a personalized vaccine (PGV001) combined with an immune booster (CDX-301) in 27 men who have had aggressive prostate cancer but currently show no signs of tumor. The goal is to see if the vaccine is safe and can train the immune system to recognize an…

This study checks the long-term safety of a balloon implant used during radiation for prostate cancer. It follows 80 people who already had the implant to see if they have any lasting bowel or urinary problems. The goal is to make sure the device remains safe over time.

This study tests if a shorter course of hormone therapy (ADT) combined with two types of radiation (brachytherapy and external beam) can safely prevent high-risk prostate cancer from returning or spreading. About 50 men with high-risk prostate cancer and a favorable genetic score…

This study tested whether adding apalutamide to standard hormone therapy helps men with prostate cancer that has spread. Over 1,000 participants received either the combination or hormone therapy alone. The goal was to see if the combination delays cancer growth and improves surv…

This early-stage study tests two oral drugs (darolutamide and abemaciclib) plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second part checks if the combination can shrink tumors befor…

This study tests whether taking omega-3 (EPA) supplements can reduce inflammation and improve quality of life in men with high-risk prostate cancer who choose surgery. 130 participants will take either fish oil or placebo capsules for six weeks before and one year after prostate …

This study compares a standard monitoring schedule for men with low-risk prostate cancer to usual care. The goal is to see if a clear plan for when to start treatment can reduce unnecessary treatments and side effects, without allowing the cancer to progress. About 2008 men with …

This study tests whether giving a higher dose of radiation (up to 81 Gy) can better control high-risk prostate cancer that hasn't spread. About 251 men will receive the treatment along with hormone therapy. Researchers will track cancer recurrence and side effects for up to 9 yea…

This study aimed to see if a person's race or ethnicity changed how well a drug combination (niraparib, abiraterone acetate, and prednisone) worked for a certain type of advanced prostate cancer. It planned to enroll Black, Hispanic, White, and Native American men whose cancer ha…

This study tested whether adding enzalutamide to standard hormone therapy (leuprolide) can delay the spread of prostate cancer in men with high-risk, nonmetastatic disease that worsened after initial treatment. About 1,068 men participated. The main goal was to see how long until…

This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread. The drug seeks out and delivers radiation to cancer cells. The goal is to find a safe dose and see if it shrinks tumors. About 33 men with either hormone-sensitive or cas…

This early-phase study tests a precise, high-dose radiation technique called SABR for men with high-risk prostate cancer. The goal is to find the highest safe dose to the prostate and pelvic lymph nodes while monitoring side effects and quality of life. About 60 participants will…

This early-phase study tests a combination of two targeted radiation drugs for men with advanced prostate cancer that has stopped responding to hormone therapy. The drugs deliver radiation directly to cancer cells. The main goal is to find the safest dose and see how many patient…

This study compares two ways of performing robot-assisted prostate removal in men with intermediate- or high-risk prostate cancer. The goal is to see which technique better preserves urinary control and sexual function while still effectively removing the cancer. About 118 partic…

This study compares three types of radiation therapy for prostate cancer to see which one controls the cancer best and causes the fewest side effects. About 500 men with prostate cancer are taking part. The goal is to find the most effective and safest way to deliver radiation.

This study was designed to compare two treatment plans for men with low-volume metastatic prostate cancer that still responds to hormone therapy. One group would receive hormone therapy plus abiraterone, while the other would get those two drugs plus chemotherapy (docetaxel). The…

This early-phase study tests a new treatment for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells while resisting the tumor's at…

This early-phase study tests a new approach for men with advanced prostate cancer that no longer responds to hormone therapy. The patient's own immune cells (T cells) are collected, genetically modified in a lab to better recognize and attack prostate cancer cells, and then infus…

This study tests a new way to deliver high-dose radiation for low- and intermediate-risk prostate cancer. The approach spares the urethra, rectum, and nearby arteries to reduce urinary and bowel side effects. About 42 men will receive this treatment and be followed for up to 2 ye…

This study tests whether a newer hormone drug (darolutamide) combined with radiation works as well as standard hormone therapy for intermediate-risk prostate cancer, but with fewer side effects on erections. About 234 men will take part. The goal is to control the cancer while he…

This study tests whether a daily high-dose omega-3 supplement (fish oil) can slow the rise of PSA levels in men whose prostate cancer has returned after initial treatment. About 40 men with a rising PSA but no visible spread will take either the supplement or a placebo for one ye…

This study compares two types of internal radiation boost (HDR vs LDR) given after external beam radiation for intermediate- or high-risk prostate cancer. The goal is to see which approach better controls the cancer while causing fewer side effects and improving quality of life. …

This early-phase study tests whether injecting a long-lasting nerve block (lidocaine and ethanol) around the prostate can slow or stop cancer growth in men with high-risk localized prostate cancer. The treatment aims to block signals from nerves that help the cancer grow. The stu…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This study tests whether placing permanent radioactive seeds directly into the prostate (brachytherapy) can control intermediate risk prostate cancer without other treatments. About 300 men with specific tumor features will receive the implant and be followed for PSA levels. The …

This study tests whether a new type of radiation therapy for prostate cancer can be safely given in just 5 sessions instead of the usual 7-8 weeks. It involves 68 men with low- to early high-risk prostate cancer. The treatment uses MRI guidance to precisely target the tumor, aimi…

This study tests a drug called 225Ac-J591 that delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to find a safe dose and see if it can lower PSA levels, a marker…

This study tests whether using advanced MRI scans to guide radiation therapy can better treat localized prostate cancer while reducing side effects. About 54 men with low to high risk prostate cancer will receive either a short course of radiation to the whole prostate or a longe…

This study looks at two common treatments for prostate cancer that hasn't spread outside the organ: surgery to remove the prostate and radiation therapy. Researchers will compare how well each method controls the cancer and prevents it from coming back. The study involves 40 adul…

This early-phase study tests a new, ultra-short radiation treatment for men with intermediate-risk prostate cancer. The approach uses MRI guidance to precisely target the prostate and the main tumor, delivering very high doses in fewer sessions. The main goal is to see if this tr…

This study tests whether a structured exercise program can slow or stop the progression of localized prostate cancer in men who are not yet receiving active treatment (active surveillance). Researchers will compare molecular and imaging markers of tumor aggressiveness between men…

This study looks at a faster type of radiation called SBRT for men with localized prostate cancer that hasn't spread. Instead of 42-45 daily treatments, SBRT delivers higher doses in just 5 sessions. The goal is to see how well it controls the cancer over time and what side effec…

This study tests whether adding sunitinib to hormone therapy can shrink or control high-risk prostate cancer before surgery to remove the prostate. About 64 participants will receive the drug combination before their scheduled prostatectomy. The main goal is to see if the cancer …

This study looks at how safe and effective the drug darolutamide is for men with prostate cancer that has not spread to other parts of the body and is no longer responding to hormone therapy. About 805 men are being observed in real-world clinics, where their doctors already chos…

This study looks at whether a 16-week home-based exercise program can slow prostate cancer growth in Black men who are monitoring their cancer without immediate treatment. The program involves high-intensity interval training (HIIT) done virtually with a coach. Researchers will m…

This early-phase trial tests a low dose of a radioactive drug called 225Ac-LNC1011 in 16 men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The drug targets a protein (PSMA) on cancer cells to deliver radiation directly. The goal …

This study tests whether adding the immunotherapy drug nivolumab to standard radiation and hormone therapy is safe and effective for men with a very aggressive type of prostate cancer (Gleason grade group 5). About 44 men will receive the combination treatment. The goal is to see…

This study tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can better control advanced prostate cancer that no longer responds to hormone therapy. About 60 adults with metastatic, castration-resistant prostate cancer will receive either one o…

This early-stage study tests a new way to give radiation for intermediate risk prostate cancer. It combines two precise radiation methods: a short internal treatment (brachytherapy) followed by three weeks of focused external beams (SBRT). The goal is to find the safest dose and …

This study tests whether combining a radioactive drug (177Lu-J591) with hormone therapy (ketoconazole) can delay the spread of prostate cancer in men whose PSA is rising despite hormone treatment. The trial includes 55 men with high-risk, non-metastatic prostate cancer. The main …

This study looks at whether aerobic exercise can lower ctDNA levels in the blood, which may help prevent cancer from returning. About 33 people who have been treated for high-risk breast, prostate, or colorectal cancer will try different amounts of weekly exercise to find the saf…

This early-phase study tests an experimental drug called MOMA-313, given alone or with another drug (olaparib), in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the dru…

This study tests whether using MRI scans to guide higher doses of radiation to the exact spot where prostate cancer has returned after surgery can better lower PSA levels. It involves 37 men whose PSA rose after prostate removal. The goal is to see if this targeted approach impro…

This study tests whether a targeted chemotherapy drug (abemaciclib) and an immunotherapy drug (atezolizumab), alone or together, can shrink or slow advanced prostate cancer that has stopped responding to hormone therapy. Nineteen adult men with metastatic castration-resistant pro…

This study compares two radiation treatments for low or intermediate risk prostate cancer in Asian patients. One is a newer, shorter course called stereotactic body radiotherapy (SBRT), and the other is standard intensity-modulated radiotherapy (IMRT). The main goal is to see whi…

This study looked at men with prostate cancer that has a moderate to high risk of coming back. It compared two treatments: hormone therapy plus high-dose radiation to the prostate alone, versus the same treatment plus radiation to the whole pelvis. The goal was to see if adding p…

This study compares two radiation therapy schedules for prostate cancer: a shorter course of 5 sessions versus a standard course of 26 sessions. The goal is to see if the shorter treatment is just as effective at controlling cancer over four years. The trial involves 161 men with…

This study tests a new way to deliver radiation for men with unfavorable prostate cancer. Using MRI guidance, doctors hope to match the success of standard treatments while reducing side effects like urinary and rectal problems. About 40 men will receive a combination of brachyth…

This study tests a treatment plan for men with prostate cancer that has spread to a few other parts of the body (oligometastatic). The treatment combines focused radiation with a hormone therapy (ADT), a drug called abiraterone, and a targeted drug called Lynparza (olaparib). The…

This study tests a new approach called extreme bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment combines a drug that blocks testosterone (darolutamide) with high doses of testosterone itself, aiming …

This early-phase study tests whether giving very high doses of radiation in just 1 or 5 sessions can safely control intermediate-risk prostate cancer. Thirty-one men will receive either a single 24 Gy dose or five 9 Gy doses using advanced image-guided technology. The main goal i…

This early-phase trial tests an experimental drug called [Ac-225]-PSMA-62 in 142 men with a specific type of prostate cancer that shows up on a PSMA scan. The drug delivers a tiny dose of radiation directly to cancer cells. The main goals are to find the safest dose and to check …

This study tests a two-step treatment plan for men with high-risk, stage IV prostate cancer that still responds to hormone therapy. The first step uses hormone therapy plus a newer drug, followed by chemotherapy plus hormone therapy. The goal is to see if this sequential approach…

This study tests if a very short course of radiation (5 treatments over 2 weeks) causes similar or fewer bowel and urinary side effects compared to a standard short course (20 treatments over 4 weeks) for men whose prostate cancer has returned after prostate removal. About 134 me…

This study looks at whether removing the prostate gland (radical prostatectomy) along with standard drug therapy helps men with prostate cancer that has spread to a few bones live longer and delay the cancer becoming resistant to treatment. About 452 men with intermediate- or hig…

This study tests if adding a stronger hormone therapy (enzalutamide) to standard treatment helps men whose prostate cancer returned after surgery. About 188 men with aggressive signs will get radiation plus either standard or enhanced hormone therapy. The goal is to see if the en…

This study tests a powerful mix of treatments—hormone therapy, a targeted drug called niraparib, and precise radiation—for men with aggressive or lymph node-positive prostate cancer. The goal is to find the safest dose and see if this approach can keep cancer from coming back for…

This study tests whether combining two drugs—atezolizumab (an immunotherapy) and tivozanib (a targeted therapy)—can shrink tumors in cancers that typically don't respond to immunotherapy alone. About 29 adults with advanced bile duct, gallbladder, breast, neuroendocrine, ovarian,…

This study looks at whether a Mediterranean diet is safe and practical for 25 Hispanic or Black men with prostate cancer who get care at LBJ Hospital in Houston. The goal is to see if this diet can be part of managing their disease. Participants will follow the diet and be monito…

This study tests whether a daily dose of green tea catechins (a concentrated form of green tea) can prevent low- to intermediate-risk prostate cancer from getting worse in men who are already monitoring their cancer without immediate treatment. Over 24 months, 115 men will receiv…

This study compares two ways of giving proton radiation to men with low-risk prostate cancer. One group gets the standard 44 treatments over about 9 weeks, while the other gets just 5 treatments over 1-2 weeks. The goal is to see if the shorter course works as well at keeping the…

This study looks at 3,000 men with prostate cancer to compare two radiation treatments: proton therapy and standard photon therapy (IMRT). The goal is to see which one causes fewer side effects and better preserves quality of life, especially bowel function. Participants are trea…

This early-phase trial tests a radioactive drug called 177Lu rhPSMA-10.1, alone or with hormone therapy, in men with high-risk prostate cancer before they have surgery to remove the prostate. The goal is to see if the drug is safe and can shrink or control the tumor. Only 6 men a…

This study tested whether taking abiraterone on an on-and-off schedule could help men with advanced prostate cancer respond to the drug longer and maintain their daily function. Nineteen men whose cancer had stopped responding to standard treatment participated. Researchers measu…

This early-stage study tests two experimental drugs (botensilimab and balstilimab) that help the immune system fight cancer. It includes about 500 adults with advanced solid tumors like lung, ovarian, or colorectal cancer that haven't responded to standard treatments. The main go…

This early-stage study tests whether giving a targeted radioactive drug (177Lu-PSMA617) followed by precise radiation (SBRT) is safe for men with hormone-sensitive prostate cancer that has spread to a few places. The goal is to see if this combination can delay or prevent the can…

This study tests a special coffee made from the Artemisia annua plant in 20 men whose prostate cancer has returned after initial treatment (surgery or radiation). The goal is to see if drinking this coffee can lower their PSA levels, a marker of cancer activity. Participants drin…

This study tests a laser device that destroys prostate cancer tumors using heat, guided by ultrasound instead of MRI. About 30 men with low- to intermediate-risk prostate cancer that hasn't spread will receive this focal treatment. The goal is to see if it's safe and effective at…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This study tests whether adding the drug abemaciclib to standard hormone therapy (abiraterone and prednisone) can slow the growth of advanced prostate cancer that no longer responds to hormone treatment alone. About 393 men with metastatic castration-resistant prostate cancer wil…

This study compares a new treatment, 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells, against standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if the new therap…

This study looks at whether testosterone levels return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and side…

This study looks at the safety of the drug TALZENNA in men whose prostate cancer has spread and no longer responds to hormone therapy, and who have a BRCA gene mutation. Only one participant is being enrolled, and all will receive TALZENNA as prescribed. The main goal is to track…

This program offered expanded access to NanoPac, a cancer treatment, for patients with advanced pancreatic, prostate, or lung cancer who could not join ongoing clinical trials. The goal was to provide treatment options for those with limited alternatives. The program is no longer…

This study tests a new robotic surgery system (Medtronic Hugo™) in 144 adults needing urologic procedures like prostate, bladder, or kidney surgery. The goal is to see if the robot helps surgeons complete the operation without switching to other methods, and to track any serious …

This early-stage study tests whether adding a chemotherapy drug (carboplatin) to a targeted radiation therapy (177Lu-PSMA-617) is safe and effective for men with advanced prostate cancer that has stopped responding to hormone therapy. About 37 participants will receive the combin…

This study tests a new long-acting drug called Debio 4228 for men with advanced prostate cancer. The goal is to see how well it lowers testosterone, which can help control the cancer. About 66 men will receive different doses of the drug as a shot. This is not a cure, but a way t…

This study tests an adaptive approach to hormone therapy for men with stage IV prostate cancer that still responds to hormone treatment. The goal is to control the cancer while possibly reducing side effects by adjusting treatment based on how the cancer responds. Only 17 men par…

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the drug can shrink tumors or slow the disease, while also monitoring side effects. Researchers will look for markers to predict wh…

This study tests a precise type of proton radiation for men with low- or intermediate-risk prostate cancer. The goal is to see if this treatment causes fewer urinary and bowel side effects compared to standard X-ray radiation. About 61 men will receive five doses of proton radiat…

This study tests a shorter, more intense radiation schedule (ultra-hypo fractionated) against the standard longer course for prostate cancer that has spread to pelvic lymph nodes. About 500 men will receive either the new or standard radiation, plus a brachytherapy boost and horm…

This study tests a new way to deliver radiation to the prostate and nearby lymph nodes in men with high-risk or unfavorable intermediate-risk prostate cancer. The approach uses MRI to find the main tumor and gives it an extra dose of radiation. The goal is to see if this method i…

This study tests whether adding radium-223 to standard chemotherapy (docetaxel) helps men with a tough-to-treat type of advanced prostate cancer live longer. About 732 men will take part. Earlier research showed the combination is safe, but it's not yet known if it works better t…

This study tests a new approach for men with intermediate-risk prostate cancer. First, doctors use electric pulses (IRE) to destroy tumor cells, followed by precise radiation (MRgRT). The goal is to see if this combination is safe and can keep cancer away for at least a year. Abo…

This study is for men with very high-risk or early-spread prostate cancer. It tests whether giving hormone-lowering medications and other drugs before surgery can shrink the cancer more than surgery alone, possibly lowering the chance it will come back. About 100 participants wil…

This study tests a treatment plan for men with high-risk prostate cancer that combines hormone therapy, external beam radiation, and a precise internal radiation implant guided by MRI. The goal is to see if this approach causes fewer side effects than standard treatments while st…

This study compares two drugs, mannitol and nitroglycerin, given during robotic surgery for prostate or bladder cancer to see if they can prevent acute kidney injury. The trial involves 90 adults with normal or mildly reduced kidney function. Researchers aim to find which drug be…

This study planned to test a focused radiation treatment (HDR brachytherapy) for men whose prostate cancer returned after earlier radiation therapy. The goal was to see if this approach could control the cancer with fewer side effects. However, the study was withdrawn before enro…

This study tests whether adding the drug talazoparib to standard treatment (enzalutamide) can help men with a certain genetic form of advanced prostate cancer live longer without their cancer getting worse. About 600 men with prostate cancer that has spread and has DNA repair gen…

This study was designed to see if surgeons could safely perform robotic surgery on prostate cancer patients from a remote location. It planned to enroll adults needing robotic prostate procedures. However, the trial was withdrawn before any participants were enrolled, so no resul…

This study tests whether giving an extra-high dose of radiation to the most aggressive parts of prostate tumors (seen on MRI) can improve cancer control and reduce side effects. About 164 men with prostate cancer will receive either this boost plus standard radiation or standard …

This study looks at whether a special gene test can help men with low-risk prostate cancer decide if it's safe to monitor their cancer closely instead of treating it right away. About 800 men with early-stage prostate cancer are taking part. The goal is to see if the test helps m…

This study tests a new way to deliver extra radiation (boost) directly to prostate tumors using a 3D ultrasound guidance system. Fifteen men with low- or favorable intermediate-risk prostate cancer will receive standard brachytherapy plus up to 4 extra iodine-125 implants placed …

This study compares an experimental oral drug, darolutamide, to standard hormone therapy (injections) for men with prostate cancer that still responds to hormones. About 250 men with early-stage or limited metastatic disease will be randomly assigned to one of the two treatments.…

This study looks at whether giving a short, precise course of radiation therapy before surgically removing the prostate is safe and doable for men with aggressive prostate cancer. Sixteen men with high-risk features (Gleason score 8 or higher or signs of tumor spread) are being t…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to target and attack cancer cells while sparing healthy ones. The study will check if the drug is safe and what dose wor…

This study is testing an experimental drug called AZD5305, a PARP inhibitor, in people with advanced solid tumors like ovarian, breast, pancreatic, and prostate cancer. The goal is to see if the drug is safe and tolerable when given alone or with other cancer treatments. About 70…

This study aimed to test two targeted radiation drugs (AAA602 and AAA802) given before surgery for men with high-risk prostate cancer that had spread to nearby lymph nodes. The goal was to see if the drugs could shrink the cancer and delay its return after the prostate and lymph …

This study tests a device that uses water vapor (steam) to destroy prostate cancer cells in men with intermediate-risk prostate cancer. About 400 men aged 50 or older will receive the treatment. The goal is to see if it can control the cancer and avoid the need for more aggressiv…

This study tests whether adding a new drug (LY2157299) to the standard treatment enzalutamide can help men with advanced prostate cancer that has stopped responding to other treatments. About 60 participants will be randomly assigned to receive either the combination or enzalutam…

This phase 3 trial compares enzalutamide alone versus enzalutamide plus radium-223 (Ra223) in 446 men with castration-resistant prostate cancer that has spread to bones but causes few or no symptoms. The goal is to see if the combination delays cancer progression on scans. Partic…

This study is for men with advanced prostate cancer that has spread and is no longer controlled by hormone therapy. Researchers are testing a drug called 177Lu-PSMA-617, which delivers radiation directly to cancer cells. The goal is to find the highest dose that can be given safe…

This study tests an experimental oral drug, MRT-2359, in people with certain advanced cancers, including lung cancer and lymphoma, that are driven by MYC genes. The trial has two phases: first, finding a safe dose, and second, checking if the drug shrinks tumors. About 174 adults…

This study tests a new drug, PF-07220060, in people with advanced solid tumors (breast, prostate, lung, and others) that have not responded to standard treatments. The drug is given alone or with hormone therapies to see if it is safe and shrinks tumors. About 362 participants wi…

This study tests whether adding the drug darolutamide to surgery can delay the return or spread of high-risk prostate cancer. About 240 men will either have surgery alone or surgery plus darolutamide taken before and after the operation. The goal is to see if the combination keep…

This study aimed to see if giving the immunotherapy drug pembrolizumab before radical prostatectomy could reduce lymph node invasion in high-risk prostate cancer patients. It was designed for men scheduled for prostate removal and lymph node dissection. However, the study was wit…

This study tests whether adding darolutamide to standard hormone therapy and radiation can delay cancer spread in men with very high-risk localized prostate cancer. About 1,100 men will receive either darolutamide or a placebo alongside their usual treatment. The goal is to see i…

This study tests whether a new tracking system (Calypso) that follows the prostate's movement during radiation can reduce long-term side effects compared to standard image-guided radiation. About 74 men with low- or intermediate-risk prostate cancer will take part. The goal is to…

This early-phase study tests whether giving higher doses of radiation to the prostate in fewer sessions is safe for men with intermediate- to high-risk prostate cancer. The treatment also targets nearby lymph nodes. The main goal is to find a schedule that limits severe side effe…

This study tests whether giving a combination of two drugs (leuprorelin and darolutamide) before prostate removal surgery can shrink tumors more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate cancer who will receive one or both dru…

This study tested whether adding enzalutamide to standard hormone therapy and chemotherapy could better control metastatic prostate cancer. Forty men with hormone-sensitive prostate cancer that had spread took part. The goal was to see if the triple combination was safe and more …

This study tests a new drug called xaluritamig in about 50 men whose prostate cancer has returned after surgery or radiation but has not spread. The main goal is to check the drug's safety and side effects. Researchers will also measure how well it controls PSA levels, a marker o…

This study compares the effects of a whole-food plant-based diet versus standard nutritional counseling on weight in overweight or obese men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy). About 76 participants will be followed for up to 26 …

This study tests whether combining two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the drug combi…

This study tests whether using MRI to guide a radiation boost to visible prostate tumors is feasible and safe. Forty men with localized prostate cancer will receive the targeted boost before or after standard whole-gland radiation. They will be followed for up to 5 years to check…

This study tests a gel called SpaceIT that is injected between the prostate and rectum before radiation therapy for prostate cancer. The gel creates space to reduce radiation reaching the rectum, aiming to prevent side effects. About 230 men with low- to intermediate-risk prostat…

This study looks at whether a special PET scan called Axumin can find prostate cancer that has returned after treatment, in patients whose usual PSMA PET scan was negative. About 50 adults with rising PSA levels will get an Axumin scan. The goal is to see if this scan spots the c…

This early-phase study tests a new PET imaging agent (89Zr-DFO-YS5) that targets a protein called CD46, found on many aggressive prostate cancer cells. About 30 men with advanced, treatment-resistant prostate cancer will receive the agent and then have PET scans to see if it can …

This study tests a new software that combines MRI images with real-time ultrasound to help doctors more accurately target and biopsy suspicious prostate lesions. The goal is to improve early detection of aggressive prostate cancer and guide better treatment decisions. The study i…

This study looks at the best time to use a special PET scan (rhPSMA-7.3) to find prostate cancer that has come back after the prostate is removed. Men with a rising PSA level will get one or two scans to see where the cancer is hiding. The goal is to catch the cancer early so tre…

This study tested a special PET scan (18F-DCFPyL) to see if it could find cancer spread in 50 men with castration-resistant prostate cancer whose standard scans were negative or unclear. The goal was to improve detection of hidden metastases. Results may help doctors choose bette…

This study tests a new type of PET/CT scan (64Cu-SAR-bisPSMA) to see if it can find prostate cancer that has returned after initial treatment. About 220 men with rising PSA levels will receive the scan. The goal is to improve detection of cancer recurrence, helping doctors decide…

This study tests a new imaging agent, 18F-DCFPyL, to see if it can better find prostate cancer that has spread in the body compared to a standard scan. About 96 adults with metastatic prostate cancer will receive both types of PET scans. The goal is to improve detection of cancer…

This study looks at whether a special PET scan called PYLARIFY can safely and accurately find prostate cancer that has spread outside the prostate gland in men with a certain type of prostate cancer (favorable intermediate risk). About 274 men will get one dose of the scan drug a…

This study looks at whether adding a PSMA PET scan can better detect significant prostate cancer in men whose MRI results are unclear or negative. About 660 men with no prior prostate cancer or biopsy will be randomly assigned to receive either standard care or an additional PSMA…

This early-phase study tests a new radioactive tracer called TRDC002 that helps doctors see prostate cancer cells on a PET scan. It is designed for people whose prostate cancer has come back or spread. The main goal is to find the best dose and timing for clear images, while also…

Men with BRCA1 or BRCA2 mutations have a higher risk of early and aggressive prostate cancer. This study looks at whether MRI scans can find these cancers earlier than standard PSA and DRE tests. About 60 men aged 50 and older with BRCA mutations will receive an MRI and then a bi…

This study tests a special PET scan (18F-DCFPyL) that targets prostate cancer cells to see if it can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 who have not had a prior prostate biopsy will receive the scan before…

This study aimed to see if a shorter, less expensive MRI (using only two types of images) could find prostate cancer as well as the standard longer MRI. The researchers planned to compare the results with tissue samples from surgery. However, the study was withdrawn before any pa…

This study looks at the tears and blood of 75 men to find differences between those with and without prostate cancer. The goal is to develop a simple test that can tell aggressive prostate cancer from slow-growing forms. Participants provide a tear sample during a clinic visit.

This study tests a radioactive tracer called 18F-DCFPyL to see if it can better find prostate cancer that has spread or come back after treatment. About 360 men with high-risk or recurrent prostate cancer will get a PET/CT scan using this tracer. The goal is to improve how doctor…

This study compares two biopsy methods—MRI fusion and micro-ultrasound—to see which better detects serious prostate cancer. About 29 men with suspected cancer or on active surveillance will be tested. The goal is to find a more affordable and accessible screening option for under…

This study is testing a new blood test that looks at genetic material (RNA) from tiny particles in the blood (exosomes) to diagnose prostate cancer. The goal is to see if this test is more accurate than current methods, potentially reducing the need for invasive biopsies. The stu…

This study aims to improve early detection of prostate cancer by adding MRI and a risk calculator to the standard PSA blood test. Researchers will enroll 4,500 men aged 55-65 in Italy to see if this approach finds more aggressive cancers while reducing unnecessary biopsies. The g…

This study tests whether analyzing ultrasound images with computer software can help doctors find prostate cancer more accurately during a targeted biopsy. About 464 men aged 55 and older with suspected prostate cancer will take part. The approach compares the new ultrasound-base…

This study explores how lifestyle factors like diet and physical activity affect prostate cancer risk in over 2000 men. Researchers aim to identify biological markers that can help personalize prevention strategies. Participants are men at high risk for prostate cancer, either wi…

This pilot study tests whether robot-assisted prostate removal can be safely performed as outpatient surgery for men with localized prostate cancer. Twenty participants will have the surgery and go home the same day if they meet discharge criteria. The goal is to see if this appr…

This study tests a 4-month community program called Men Moving Forward for African-American men who have finished prostate cancer treatment. The program includes twice-weekly sessions to help them eat more fruits and vegetables, exercise more, and improve their body composition. …

This study tests a new surgical technique called NeuroSAFE during robotic prostate removal for prostate cancer. The goal is to see if it helps men keep erectile function and urinary control better than standard surgery. About 407 men who are potent and continent before surgery wi…

This study compares two pain control methods after robotic prostate removal: one using opioids and one using only non-opioid medicines like ketamine, ketorolac, and acetaminophen. About 100 men aged 40-75 with prostate cancer will participate. The goal is to see if the opioid-fre…

This study compares two types of internal radiation therapy (brachytherapy) for men with early-stage prostate cancer. One uses low-dose radiation seeds placed permanently, the other uses high-dose radiation given in short sessions. The goal is to see which approach leads to bette…

This study looks at whether giving men a deeper level of muscle relaxation during robotic prostate surgery can lower the pressure used in the abdomen during the operation and reduce pain afterward. About 139 men having elective robotic prostatectomy will be randomly assigned to e…

This study looks at whether giving a numbing shot (TAP block) at the start or end of robotic prostate surgery helps men feel less pain afterward. About 94 men with prostate cancer will take part. The goal is to find the best timing to reduce pain and the need for strong painkille…

This study tests whether acupuncture can reduce frequent nighttime urination (nocturia) in prostate cancer survivors. Researchers will enroll 60 survivors who wake up at least twice a night to urinate. Participants will receive 10 acupuncture sessions, and the study will measure …

This study tests a new way to give radiation for prostate cancer that aims to reduce side effects. Twenty men with intermediate-risk prostate cancer will receive a lower dose of radiation to the whole prostate but a higher dose to the tumor itself, using a special MRI-guided mach…

This study tests whether a gentle electrical stimulation device (AcuTENS) can help reduce pain and anxiety during a prostate biopsy. About 53 men having their first biopsy will receive either the active device or a placebo, along with standard pain relief. The goal is to see if t…

This study looks at whether a 16-week home exercise program can help Black and Hispanic patients with breast, colorectal, or prostate cancer become more active while on chemotherapy. Participants are split into three groups: supervised exercise via Zoom, unsupervised exercise, or…

This study tests whether using a bedside lung ultrasound during robotic prostate or bladder cancer surgery helps doctors set the breathing machine pressure more precisely. The goal is to prevent lung collapse and reduce breathing complications after surgery. About 88 adults with …

This study tests a gel called SpaceOAR Vue that is placed between the prostate and the bowel before radiation therapy. The goal is to see if it lowers the chance of bowel problems after treatment. About 500 men with intermediate-risk prostate cancer are taking part.

This study tests whether a pelvic floor muscle exercise program, taught by a physical therapist before and after prostate removal surgery, can help reduce or shorten urinary leakage. About 32 men with prostate cancer will participate. The main goal is to see if the program is pra…

This study compares two types of radiation therapy—proton beam therapy and IMRT—for men with low- or intermediate-risk prostate cancer. Both treatments aim to cure the cancer by targeting the prostate while sparing healthy tissue, but they may cause different side effects like bo…

This study tests whether live exercise coaching plus a personalized digital app can improve quality of life for cancer survivors. About 146 adults with breast, lung, prostate, colorectal, or other cancers who had treatment in the last year will use the program for 18 months. Rese…

This study looks at whether exercise, supportive counseling, and a stimulant drug (methylphenidate) can help reduce severe fatigue in men with prostate cancer who are receiving radiation and hormone therapy. About 175 participants will try different combinations of these treatmen…

This study tests whether a culturally adapted strength training program, done together with a caregiver, is feasible and beneficial for Hispanic prostate cancer survivors and their caregivers. The program involves remote group exercise classes over 3 months, with a 3-month follow…

This study follows nearly 90,000 farmers, their spouses, and children in Iowa and North Carolina to see how pesticides and other farm exposures affect their health. Researchers track who develops cancer or other diseases over many years. The goal is to find out which chemicals or…

This study is a registry that collects information on 500 men with metastatic castration-resistant prostate cancer who are treated with PSMA theranostics. The goal is to track how well the treatment lowers PSA levels and to monitor any side effects. The registry does not test a n…

This study looks back at the results of robotic prostate surgery in over 1,500 men with prostate cancer. Researchers want to understand patient traits and how they relate to surgery outcomes, including cancer return and survival. The goal is to improve future treatment decisions.

This observational study looks at 15 specific proteins on prostate cancer cells to understand how common they are and whether they can predict survival. Researchers will study tissue samples from 1,600 men with different types of prostate cancer, including those that have spread.…

This study looks at ways to help people who have inherited gene changes that raise cancer risk. The goal is to see if certain tools can help them follow recommended cancer screening and prevention steps, and also share their genetic test results with family members. About 720 adu…

This study looks at whether a new screening method using PHI and mp-MRI can find prostate cancer earlier in men with certain gene mutations (DRG). The goal is to see if this approach works better than the current standard of DRE and PSA tests. About 320 men with prostate or bladd…

This study looks at whether removing lymph nodes during prostate removal surgery helps men with intermediate-risk prostate cancer. About 3,650 men will be randomly assigned to have lymph nodes removed or not. The goal is to see if the extra surgery lowers the chance of cancer com…

This study looks at whether breath, DNA, and imaging can help doctors predict how prostate cancer and healthy tissues react to a precise type of radiation called SBRT. Sixty men with low- or intermediate-risk prostate cancer will provide breath and blood samples before and after …

This study follows nearly 2,000 men with newly diagnosed prostate cancer to see if certain genes make the cancer more likely to spread. Researchers collect blood or tissue samples and track health outcomes over time. The goal is to better understand genetic risk factors, not to t…

This study aimed to compare two different physical therapy programs for men who still have urine leakage more than a year after prostate cancer surgery. The researchers planned to measure how much urine leaked and how well participants could balance. However, the study was withdr…

This study follows over 64,000 adults who grew up on farms to see if early-life exposures to pesticides and other agricultural factors are linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track cancer and other d…

This study tests whether artificial intelligence (AI) can help doctors outline the prostate on ultrasound images more quickly and accurately during a type of radiation treatment called brachytherapy. About 36 adults with prostate cancer will take part. The goal is to see if AI-as…

This study uses MRI scans to understand how prostate cancer changes after radiation therapy. Researchers want to see if MRI can help doctors manage treatment better and sooner. About 120 adults with prostate cancer who are getting radiation will take part. The goal is to learn, n…

This study tests whether a blood protein called chromogranin A (CgA) can help predict if prostate cancer will come back after radiation therapy. Researchers will measure CgA levels before, during, and after treatment in 118 men with prostate cancer. The goal is to see if changes …

This study compares two types of urine samples—expressed prostatic secretion (EPS) and post massage urine (PMU)—to see which one more accurately predicts whether a prostate biopsy will find cancer. About 243 men scheduled for a prostate biopsy will provide both samples. The goal …

This study explores whether advanced MRI techniques can detect early changes in prostate cancer and surrounding tissues during radiation therapy. By monitoring these changes, doctors hope to adjust treatment to reduce side effects and improve outcomes. The study involves 38 men w…

This study looks at whether men with certain inherited gene changes (BRCA1, BRCA2, or mismatch repair genes) have a higher chance of getting prostate cancer. About 3,500 men aged 40-69 with or without these gene changes will get yearly PSA tests. The goal is to learn how often pr…

This study collects tissue and blood samples from 156 people with advanced prostate, kidney, or bladder cancer to find genetic markers that predict how well different treatments will work. Participants give a biopsy of a growing tumor before starting their planned therapy, which …

This study was designed to see if the drug ruxolitinib could change immune cells in prostate tumors. Men with prostate cancer would take the drug for 28 days before surgery to remove the prostate. However, the study was withdrawn before any participants were enrolled, so no resul…

This study was designed to test whether an informational website helps men with low-risk prostate cancer understand their treatment options and make more informed decisions. Researchers planned to measure patient knowledge and decision-making confidence using questionnaires. Howe…

This study looks at four different tools to help people who have had cancer improve their diet and physical activity. About 353 cancer survivors will try these tools to see which ones work best. The goal is to find simple ways to help survivors follow healthy lifestyle guidelines…

This study looks at how often bowel leakage (fecal incontinence) happens in prostate cancer survivors who had a specific type of radiation therapy. Researchers will check 200 patients to see if the radiation dose to the anal muscles affects the severity of leakage. The goal is to…

This study looked back at 3350 men with early-stage prostate cancer who chose watchful waiting instead of immediate treatment. Researchers analyzed medical records and biopsy samples to find which factors, like PSA levels and Gleason scores, best predict how the disease will prog…

This study is testing a new system that combines aging, mental health, and social needs checks for cancer patients aged 65 and older. The goal is to help doctors provide care that fits each patient's life. About 35 people with different cancers will try it during their first visi…

This study tests whether a special PET scan (18F-DCFPyL) done before prostate removal surgery can predict if prostate cancer will return. About 175 men with high-risk prostate cancer will get the scan, then have surgery, and be followed for up to 5 years. The goal is to see if th…

This study works with Spanish-speaking Latiné men who have had prostate cancer surgery. Researchers want to learn about their quality of life and decision-making challenges, especially around issues like erectile dysfunction. The goal is to create better educational videos and re…

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. Researchers will analyze records from 100,000 patients to see how long they live after diagnosis. The goal is to better understand c…

This early-phase study looks at whether a short course of hormone therapy can make prostate cancer cells show up brighter on PSMA PET scans. About 9 men with recurrent prostate cancer will take standard hormone pills for 4 weeks and get a scan before and after. The goal is to see…

This study tests a method called KIM that uses small gold markers in the prostate to track movement during radiation therapy. If the prostate moves more than 3mm, the radiation beam pauses and is realigned. The goal is to see if this technique is practical and accurate for everyd…

This study looks at whether hormone therapy (like Lupron or Casodex) changes thinking abilities in men 65 and older with prostate cancer. Researchers will compare thinking and daily function in men starting or already on hormone therapy versus those not on it. The goal is to unde…

This study tests whether a smartphone app can help African American men learn about prostate cancer and complete a home-based PSA test. About 80 men aged 55-69 in Oklahoma who haven't had a PSA test in two years will use either a new app or an existing government app for 30 days.…

This study is testing a small, implantable device that can be placed inside a prostate tumor to see how it responds to different cancer drugs. The goal is to find out if this approach is safe and feasible in 35 men scheduled for prostate removal surgery. If successful, this metho…

This study aims to understand how much information people can remember about their own cancer screening and diagnosis. Researchers will test whether giving extra time or resources helps people recall more accurate details. The study was withdrawn before enrolling any participants…

This study looks at whether group doctor visits over video (telemedicine) are a practical and acceptable way to follow men with low-risk prostate cancer who are on active surveillance. About 88 men will be randomly assigned to either a group video visit or a one-on-one video visi…

This study looks at whether a 2-minute animated video can help men with low- to intermediate-risk prostate cancer better understand their treatment options. About 400 men will watch the video and then choose between active surveillance, focal therapy, or standard treatment. Resea…

This study was designed to observe and measure certain proteins (chemokines) in the blood, urine, and tumors of people with prostate cancer. The goal was to see how these protein levels change over time and relate to the disease. However, the study was withdrawn before any partic…

This study follows 490 Brazilian men with low-risk prostate cancer who choose active surveillance instead of immediate treatment. Researchers track how often the cancer becomes more aggressive and how many men avoid treatment over time. The goal is to see if this watch-and-wait a…

This study looks at the DNA of nearly 24,000 men with prostate cancer to find inherited genetic changes that increase risk. It focuses on younger men and those with a family history, where genes may play a bigger role. The goal is to better understand why some men get prostate ca…

This study collects DNA from over 21,000 New York cancer patients to look for inherited gene changes linked to several cancer types. It is an exploratory project that does not offer treatment but aims to find clues for future research. Participants include people with breast, col…

This study looks at whether men can safely have a prostate biopsy without taking antibiotics beforehand. The biopsy is done through the perineum (the area between the testicles and anus), which already has a low risk of infection. Researchers will compare infection rates in 300 m…

This study tests whether a new total-body PET scanner can improve cancer imaging for people with prostate cancer, breast cancer, or neuroendocrine tumors. Nine participants will receive one of three FDA-approved imaging agents to see how well the scanner captures tumor activity. …

This study looks at how robotic surgery for prostate, bladder, or kidney cancer affects patients' finances. About 120 adults who had surgery in the last year will fill out questionnaires about money worries, medical costs, and travel expenses. The goal is to understand which pati…

This study looks at 30 men with high-risk prostate cancer who are getting radiation and hormone therapy. Researchers use special scans and genetic tests to see if they can predict early on how well the treatment is working. The goal is to better understand which patients might ne…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to bank these samples for future research on how radiation affects the prostate. However, the study was withdrawn before enrolling any participants, so no data …

This study watches 200 men with prostate cancer who are getting hormone therapy (androgen deprivation therapy) to see how it affects their heart health. Researchers will use heart ultrasounds, blood tests, and surveys to track changes and look at how factors like race, income, an…

This study follows people who previously received an experimental CAR-T cell therapy from AvenCell for cancers like lymphoma, leukemia, or prostate cancer. The goal is to track long-term side effects, including new cancers, nerve problems, or immune disorders. About 178 participa…

This study follows 304 men in Martinique diagnosed with prostate cancer starting in 2020. Researchers use digital questionnaires to track quality of life, focusing on sexual and urinary issues. The goal is to gather real-world data to reduce health disparities and improve cancer …

This study aims to find non-invasive biomarkers in blood and urine that can help track prostate cancer progression without relying solely on repeated biopsies. Researchers will follow 500 men with low-to-high risk prostate cancer, collecting standard medical samples and additiona…

This early-stage study tests whether a special MRI scan using a safe, injected substance (hyperpolarized bicarbonate) can measure acidity levels in prostate tumors. The goal is to see if this imaging method is feasible and safe in a small group of men scheduled for prostate remov…

This study looks at why some prostate cancer survivors have trouble with thinking and memory (called cancer-related cognitive dysfunction). Researchers want to see how anxiety, depression, and insomnia play a role, along with social factors and cancer treatments. About 200 surviv…

This study tests a new radioactive tracer called 18F-FluorThanatrace to see how active a protein called PARP-1 is in prostate cancer tumors. About 30 men with prostate cancer will get a PET/CT scan before surgery. The goal is to see if the scan can find cancer better, not to trea…

This study observes about 1,000 prostate cancer patients who are taking the drug ORGOVYX as part of their normal treatment. Researchers want to see how safe and effective the drug is in real-world settings, not just in controlled trials. They will track side effects, quality of l…

This study checks if a special type of PET scan (PSMA PET) is more accurate than usual scans for seeing prostate cancer and how it responds to treatment. About 58 people with prostate cancer that is new or getting worse will take part. The goal is to see if this scan can better p…

This study looks at whether screening for social needs (like food or housing), connecting survivors with community health workers, and training clinic staff on anti-racism can improve quality of life for Black breast and prostate cancer survivors. About 1,100 survivors in Washing…

This study looks at a new approach to genetic testing for people with ovarian, prostate, or pancreas cancer. Instead of always sending patients to a genetic counselor, doctors offer the test and counselors share results by phone. The goal is to see how this affects patient distre…

This study collects tissue, blood, and other fluid samples from men with prostate conditions (including those without cancer) to help researchers understand what causes prostate cancer, why some cancers are more aggressive, and why some respond or resist treatment. The samples ma…

This study tests a program that helps doctors follow guidelines when ordering imaging tests for prostate cancer. About 58 VA doctors and staff took part. The goal is to reduce inappropriate scans and ensure the right tests are used for each patient.

This study follows 7,500 men aged 50-74 to see if a modern screening program using PSA, a biomarker blood test, and MRI scans leads to fewer prostate cancer deaths compared to standard PSA testing alone. Participants were previously invited for screening, and researchers track th…

This study looks at whether the Decipher tumor test can predict aggressive prostate cancer with the same accuracy in African-American men as in non-African-American men. The test was developed mainly from samples of European descent, but African-American men have higher rates of …

This study involves 100 men with high-risk, localized prostate cancer who are scheduled for radiation and hormone therapy. Researchers will use an advanced MRI technique called Restriction Spectrum Imaging (RSI-MRI) to see if it can predict how well the cancer responds to treatme…

This study looks at how a person's sense of coherence—their ability to cope with stress—affects their quality of life after radiation for prostate cancer. Researchers will follow 250 men for one year, asking them to fill out questionnaires about their well-being and symptoms. The…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find hard-to-see tumors during biopsies or ablation procedures. About 3,900 adults with certain cancers or growths will take part. The goal is to see if this tool can place the …

This study looks at whether a 12-week survivorship program can be added to the usual follow-up care for men with advanced prostate, kidney, bladder, testicular, or penile cancer. Researchers will ask 72 men about their experience to see if the program is practical and helpful. Th…

This study looks at how two different prostate cancer medications, darolutamide and enzalutamide, affect thinking skills like memory and attention. About 111 men with advanced prostate cancer will take one of the two drugs and complete computer-based brain tests over time. The go…

This study looks at whether a man's genetic profile can help doctors decide who should be screened for prostate cancer. About 300 men aged 55-69 will have their genes checked and those with higher genetic risk will be offered a prostate biopsy. The goal is to see if this approach…

This study looks at whether detailed analysis of MRI scans (called radiomics) can help doctors better predict how aggressive a prostate cancer is and whether it will come back soon after surgery. Researchers will study 125 patients who have prostate MRI before surgery. The goal i…

This study looks at whether a genetic test called the Genomic Prostate Score (GPS) can help doctors better choose men for focal therapy, a treatment that targets only the cancer while sparing healthy prostate tissue. Researchers will review past data and tissue samples from 241 m…

This study looks at whether artificial intelligence (AI) can help doctors quickly and accurately find men with prostate cancer who are eligible for a clinical trial. Researchers will use an AI tool to rank patients by how likely they are to qualify, then compare the results to tr…